Insomnia Tracks With Inflammatory Burden in Adults 80 and Older
Insomnia in the oldest-old is not just a sleep complaint; it appears to travel with measurable systemic inflammation. In a cross-sectional study of 384 geriatric outpatients aged 80 years and older, insomnia severity rose in parallel with higher neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index, pointing to a biologic signal that can be extracted from routine blood counts.
The prevalence itself was hard to ignore: insomnia was identified in 38.5% of participants. In a cohort this old, sleep fragmentation often collides with multimorbidity, polypharmacy, pain, frailty, and autonomic stress. The data fit that bedside reality, showing significant positive correlations between Insomnia Severity Index scores and chronic disease burden, medication count, and the three inflammatory indices, all with p values below 0.001.
One finding stood out from the rest. After full covariate adjustment, systemic immune-inflammation index and neutrophil-to-lymphocyte ratio remained independently associated with insomnia severity, while platelet-to-lymphocyte ratio no longer held significance.
Why Inflammation May Matter for Sleep in the Oldest-Old
The biological rationale is plausible and clinically familiar. Sleep disruption can amplify sympathetic activation, alter hypothalamic-pituitary-adrenal signaling, and favor a proinflammatory state marked by higher cytokine activity. In parallel, systemic inflammation may worsen sleep continuity through fatigue, discomfort, pain amplification, and changes in central arousal regulation. In older adults, where baseline inflammatory tone is often elevated, even modest physiologic shifts can become clinically visible in symptom burden.
This study did not measure cytokines such as interleukin-6, tumor necrosis factor-alpha, or C-reactive protein directly, but the hematologic indices used here are attractive because they are cheap, repeatable, and embedded in routine practice. NLR and SII derive from standard complete blood count parameters and can be calculated without specialized assays. For geriatric clinics that already track medications, comorbidities, and functional vulnerability, those indices offer a practical way to flag patients whose insomnia may reflect more than poor sleep hygiene or age-related awakening alone.
The pattern also makes physiologic sense in the context of chronic disease burden. Participants with insomnia had higher inflammatory markers alongside more medications and more comorbidity, suggesting that sleep disturbance may be entangled with the broader inflammatory load of aging rather than standing apart from it. In the oldest-old, insomnia often presents as a marker of systemic strain rather than an isolated nocturnal symptom.
NLR and SII Emerged as the Strongest Blood-Based Signals
The statistical picture was clear. Insomnia Severity Index scores correlated positively with NLR, PLR, and SII, but the adjusted model narrowed the list of markers that remained independently informative. SII retained a significant association with insomnia severity, with β = 0.07 and p < 0.001. NLR also remained significant, with β = 0.666 and p = 0.004. PLR fell out of the model after adjustment, suggesting that the platelet component may be less specific in this age group once other clinical factors are accounted for.
That hierarchy matters at the bedside. NLR captures a balance between innate immune activation and lymphocyte-mediated regulation, while SII integrates neutrophils, lymphocytes, and platelets into a single composite measure. In older adults with multimorbidity, those composite signals may better reflect the inflammatory burden relevant to insomnia than platelet count alone. The findings argue for a more nuanced interpretation of routine blood work in geriatric sleep assessment.
The study also reinforces how common insomnia is in advanced age. The 38.5% prevalence in this cohort is high enough to warrant routine attention, especially because sleep loss in older adults can aggravate daytime function, mood, balance, cognition, and overall quality of life. Even when insomnia is not the primary reason for a visit, it may be one of the earliest clues that inflammatory stress, medication effects, or chronic illness burden is accumulating.
What a Cross-Sectional Design Can and Cannot Tell Clinicians
The design answer was association, not causation. A cross-sectional snapshot cannot determine whether inflammation drives insomnia, whether insomnia intensifies inflammation, or whether both are shaped by a third process such as frailty, chronic disease severity, pain, depression, or sleep-disordered breathing. Obstructive sleep apnea, for example, can raise inflammatory markers and disrupt sleep, but it was not separated out here as a causal explanation.
Still, the signal is clinically credible. In a geriatric outpatient setting, a patient with persistent insomnia and elevated NLR or SII may deserve closer review of inflammatory comorbidities, medication burden, and sleep-disrupting disease processes. The study does not justify using these markers as standalone diagnostic tests for insomnia, but it does support their potential value as accessible adjuncts when clinicians are trying to determine whether sleep complaints are part of a broader systemic picture.
The participant group also deserves careful framing. These were geriatric outpatients aged 80 years and older, a subgroup in which evidence has been notably sparse. In that age band, physiologic reserve is reduced and the clinical meaning of minor biomarker shifts can differ from that in younger adults. A biomarker that is merely interesting in middle age can become clinically useful in the oldest-old if it helps identify who is carrying the heaviest inflammatory load.
Geriatric Sleep Care May Need a Wider Lens
The practical message is straightforward: insomnia in very old adults may be inseparable from systemic inflammation, comorbidity, and medication burden. Routine hematologic indices already available in most clinics could help clinicians stratify which patients carry a heavier biologic burden, especially when sleep symptoms are persistent or disproportionate to obvious triggers.
Future work needs to move beyond association. Longitudinal studies should test whether elevated SII or NLR predicts incident insomnia, whether worsening sleep raises these markers over time, and whether anti-inflammatory interventions alter sleep severity in the oldest-old. Until then, the current data support a cautious clinical reading: in geriatric practice, insomnia may be telling part of an inflammatory story, and routine blood counts may already contain some of the clues.